 |
|
Pulmonary InfectionsThe Minnesota Randomized Prospective Trial of Cyclosporine vs Azathioprine-Antilymphocyte Globulin for Immunosuppression in Renal Allograft Recipients
Uwe J. Hesse, MD;
David S. Fryd, PhD;
Satya N. Chatterjee, MD;
Richard L. Simmons, MD;
David E. R. Sutherland, MD, PhD;
John S. Najarian, MD
Arch Surg. 1986;121(9):1056-1060.
Abstract
• Nineteen of 224 renal allograft recipients who were prospectively randomized to receive either cyclosporine (n = 117) or azathioprine sodium—antilymphocyte globulin (n = 107) for immunosuppression suffered from one period of pneumonia (14 azathioprine and five cyclosporine recipients); two recipients of azathioprine had two episodes. Four patients in the azathioprine group and one in the cyclosporine group died, for mortalities of 3.7% and 0.85%, respectively. The percentage of pneumonia-free patients at one year was 96.3% in the cyclosporine group while it was 90.8% in the azathioprine group. Nondiabetics, women, and recipients of grafts from living related donors were at a statistically lower risk of developing pneumonia when treated with cyclosporine. Viral (cytomegalovirus), fungal (Candida, Aspergillus), and multibacterial causes of pneumonia each occurred with a similar incidence.
(Arch Surg 1986;121:1056-1060)
Author Affiliations
From the Department of Surgery, University of Minnesota Hospitals, Minneapolis. Dr Hesse is now with the Department of Surgery, University of Cologne, Federal Republic of Germany.
Footnotes
Accepted for publication March 3, 1986.
Reprint requests to Box 280, University of Minnesota Hospitals, 420 Delaware St SE, Minneapolis, MN 55455 (Dr Sutherland).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
|
